Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Authored Items
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Value-Based Care
,
Conference Highlights ASCO
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
Chase Doyle
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Chase Doyle
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Lymphoma
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
Chase Doyle
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life
Chase Doyle
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Value-Based Care
First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma
Chase Doyle
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
,
Lymphoma
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Breast Cancer
Clinical Decision Support Helps Compliance with Evidence-Based Pathways
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Value-Based Care
Cemiplimab Cost-Effective for Advanced Cutaneous Squamous-Cell Carcinoma
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Value-Based Care
Germline Alterations Analysis Has Actionable Value in Selecting Targetable Treatments for Patients with Advanced Cancer
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Value-Based Care
Intratumoral Injection of Cisplatin and Vinblastine, with or without Pembrolizumab, Improves Intracellular Transport in Patients with Advanced Solid Tumors
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
,
Lymphoma
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma
Chase Doyle
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Lymphoma
Venetoclax plus Intensive Chemotherapy Shows Promising Results in All Patients with Acute Myeloid Leukemia
Chase Doyle
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML
Chase Doyle
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
,
Value-Based Care
Applying CAR T-Cell Therapies to Solid Tumors: Overcoming Current Challenges
Chase Doyle
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Immunotherapy
Patient Navigators, Clinician Education Can Remove Barriers to Enrollment in Clinical Trials
Chase Doyle
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Value-Based Care
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Renal-Cell Carcinoma
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting
Chase Doyle
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Immunotherapy
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Value-Based Care
Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Value-Based Care
Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Multiple Myeloma
Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Emerging Therapies
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Value-Based Care
Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Value-Based Care
Next-Generation Sequencing Could Help Treatment Decisions in Acute Myeloid Leukemia
Chase Doyle
August 2018 Vol 11, Special Issue
in
Leukemia
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
August 2018 Vol 11, Special Issue
in
Pancreatic Cancer
Discussing Costs with Your Patient Can Reduce Financial Toxicity
Chase Doyle
August 2018 Vol 11, Special Issue
in
Value-Based Care
PARP Inhibitors Least Cost-Effective as Maintenance Therapy in Advanced Ovarian Cancer
Chase Doyle
August 2018 Vol 11, Special Issue
in
Value-Based Care
LOXO-292 Highly Effective in RET-Positive Cancers
Chase Doyle
August 2018 Vol 11, Special Issue
in
Emerging Therapies
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer
Chase Doyle
August 2018 Vol 11, Special Issue
in
Breast Cancer
CAR T-Cell Therapy Yields Impressive Responses in Aggressive Non-Hodgkin Lymphoma
Chase Doyle
August 2018 Vol 11, Special Issue
in
Breast Cancer
Overcoming Barriers to Cost Transparency in Cancer Care
Chase Doyle
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Value-Based Care
Novel Cancer Drugs Must Adopt Value-Based Pricing
Chase Doyle
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Value-Based Care
Patients with Curable Cancer Experience Significant Symptom Burden and Hospitalization
Chase Doyle
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Value-Based Care
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Multiple Myeloma
Adoptive T-Cell Therapy: Ready for Prime Time
Chase Doyle
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Immunotherapy
Oncologists Must Begin to Discuss Financial Toxicity with Patients
Chase Doyle
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Value-Based Care
BEACOPP Regimen Superior to ABVD in Newly Diagnosed, Advanced Hodgkin Lymphoma
Chase Doyle
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Value-Based Care
Increased Utilization of Biosimilars in Oncology Could Save Payers Millions
Chase Doyle
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Value-Based Care
Value Frameworks Unreliable in Assessing Novel Hematologic Therapies
Chase Doyle
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Value-Based Care
Frontline Use of Bendamustine plus Rituximab Cost-Effective for Indolent B-Cell Non-Hodgkin Lymphoma
Chase Doyle
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Value-Based Care
ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia
Chase Doyle
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Value-Based Care
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Chase Doyle
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Value-Based Care
Induction Therapy plus Autologous Stem-Cell Transplantation Still Cost-Effective for Newly Diagnosed Multiple Myeloma
Chase Doyle
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Value-Based Care
Healthcare Resource Utilization High in Patients with Relapsed or Refractory Multiple Myeloma
Chase Doyle
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Where Quality Meets Cost: Payers’ Perspective on Pathways
Chase Doyle
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Costs of Treatment-Related Adverse Events Higher with Docetaxel than with Nivolumab in Advanced Lung Cancer
Chase Doyle
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Cost of Chemotherapy for Breast Cancer Varies Widely Across Regimens
Chase Doyle
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
How to Reduce Financial Toxicity in Patients with Cancer
Chase Doyle
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Transition from Branded to Generic Cancer Drugs Significantly Increases Treatment Cost-Effectiveness
Chase Doyle
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Out-of-Pocket Costs Linked to Reduced Adherence to Oral Oncolytics
Chase Doyle
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Clinical Pathways and the Oncology Medical Home: First Steps to Value-Based Patient Care
Chase Doyle
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Value-Based Purchasing: Implications for Hematology
Chase Doyle
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Redesigning the Payment Model for Acute Leukemia: Benefits and Challenges of the Episode-of-Care Model
Chase Doyle
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Measuring Value in Healthcare to Improve Quality
Chase Doyle
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
Chase Doyle
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
Chase Doyle
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Value-Based Healthcare Delivery: The Agenda for Oncology
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
CAR-T Cells: The Transplants of the Future
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Value Propositions in Oncology: The Physician Perspective
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Anthem’s Clinical Pathways Demonstrate Value: The Payer Perspective
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
ASCO’s Value Initiative: A New Framework Seeking to Standardize Patient–Physician Interactions
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Communication Gap with Oncologists, Not Cost, Tops Patients’ Value Priorities
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Immunotherapies Steal the Show at ASCO 2015
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Immunotherapy
Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma
Chase Doyle
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Immunotherapy
Brentuximab Cost-Effective After Transplant
Chase Doyle
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Economic Value of Survival Gains for MDS Could Exceed $100 Billion
Chase Doyle
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Last modified: April 23, 2015
